Amedica Corporation Reports First Quarter 2015 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Amedica Corporation Reports First Quarter 2015 Financial Results

SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq: AMDA ), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, today announced financial results for the first quarter ended March 31, 2015.

First Quarter 2015 Highlights

  • Completed SNAP clinical trial enrollment
  • Submitted for 510(k) clearance of cervical CsC device
  • Kyocera officially named as approved secondary supplier of silicon nitride devices
  • Continued robust scientific publication strategy of one peer-reviewed publication per month
  • Began two feasibility studies and advanced several OEM and Private Label discussions

"During this past quarter, we have accomplished a great deal in a short amount of time," said Dr. Sonny Bal, chairman and CEO of Amedica Corporation. "We remain committed to rapidly upgrading our long-ignored metals product line as we experienced larger than anticipated declines in sales this quarter, which also affected our silicon nitride business to a lesser extent due to its pull-through effect. We've listened to our surgeons and agents, and have made the appropriate changes this quarter to ensure increased adoption of our material going forward. Despite increased share price volatility from past financial transactions, I firmly believe that our recent operational, clinical, and regulatory accomplishments have positioned Amedica to capture additional market share, enhance our ability to show the advantages of silicon nitride, and promote wider adoption of the material across a number of biomedical platforms."

First Quarter 2015 Financial Results

Total product revenue decreased by 18% during the first quarter of 2015 to $4.7 million, as compared to $5.8 million in the prior year period. This was primarily attributable to a 37% decrease, or $1.2 million, in the Company's non-silicon nitride business due to lower metals sales. This decrease was partially offset by a 7% increase in silicon nitride ceramic product revenue over the prior-year period.

Gross profit for the quarter totaled $3.2 million, compared to $4.1 million in the same period last year. Gross margin percentage for the first quarter 2015 was 68%, compared to 72% for the first quarter of 2014. Excluding the impact of excess or obsolete inventory for both years, first quarter 2015 gross margins ended at 75% of total sales, as compared to 79% during the prior year period. This decline in gross margins was due to private label sales during the first quarter of 2015, which have lower gross margins due to lower selling prices, but higher operating contribution margins since no commissions are paid and require less operating expenses to support these sales.

Operating expenses for the first quarter of 2015 declined by 12%, or $1.0 million, from the prior year period, to $7.2 million. This year-over-year decline in operating expenses is primarily due to the actions taken by the Company to simplify the organization and align financial objectives earlier in the year, as well as lower commission costs and stock-based compensation expense during the first quarter of 2015.

Net loss for the first quarter was $5.4 million, compared to $4.7 million in the prior-year period, primarily as a result of lower year-over-year revenue and increased interest expense incurred during the quarter.

Adjusted EBITDA, which is defined as earnings before deductions for interest, taxes, depreciation, amortization, non-cash stock compensation expense, change in fair value of our derivative liabilities, offering costs, and loss on extinguishment of debt for the first quarter 2015 was ($2.9) million, compared to ($2.1) million for the prior year period. This decline in adjusted EBITDA was primarily attributable to severance-related expenses of $0.7 million during the first quarter of 2015 and decreased sales during the first quarter of 2015.

Cash and cash equivalents totaled $14.9 million, while total principal debt obligations were $24.3 million as of March 31, 2015.

2015 Business Outlook

The Company revises its previously stated estimates of increased 2015 silicon nitride sales this year to 15-20% growth, thus equating to a total annual revenue range of $19-$20 million. Due to the estimated decline in annual revenue, the Company expects the impact from the previously announced financial and operational alignment actions to deliver $5-$7 million of annualized operating profit benefit. These changes are anticipated to reduce total cash burn, increase financial sustainability, and strengthen the balance sheet, positioning the Company to maintain compliance with all debt covenants into Q4 of this year and become operating cash flow breakeven during the second half of 2016.

Additionally, the Company maintains its previously stated guidance of four additional OEM or private label partners to be announced during the balance of 2015.

Conference Call

The Company will hold an investor conference call to discuss the results today, May 7, 2015 at 5:00 p.m. Eastern Time. The Company invites all interested parties to join the call by dialing (855) 455-6055, any time after 4:50 p.m. Eastern Time on May 7 th . The Conference ID number is 25966628. International callers should dial (484) 756-4308. A live audio webcast of the call will be available through a link on the Company's web site, at http://investors.amedica.com/events.cfm . The call will be archived telephonically for one week and can be accessed by calling (855) 859-2056 in the U.S., or (404) 537-3406 from outside the U.S. The Conference ID for the audio replay is 25966628.

About Amedica Corporation

Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, the world's largest ceramic manufacturer. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com .

Non-GAAP Financial Measures

This press release includes the following "non-GAAP financial measures" as defined by the Securities and Exchange Commission (SEC): Adjusted EBITDA and gross margin before deducting the provision for excess and obsolete inventory. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation of, or as a substitute for, the financial information prepared and presented in accordance with generally accepted accounting principles (GAAP). For a reconciliation of these non-GAAP financial measures to the nearest comparable GAAP measure, see "Reconciliation of Non-GAAP Financial Measures" included in this press release.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include specifically, but are not limited to; the Company's revision of its previously stated estimates of increased 2015 silicon nitride sales this year to 15-20% growth, thus equating to a total annual revenue range of $19-$20 million and the Company's expectation that the impact from the previously announced financial and operational alignment actions will deliver $5-$7 million of annualized operating profit benefit and that these changes are anticipated to reduce total cash burn, increase financial sustainability, and strengthen the balance sheet, positioning the Company to maintain compliance with all debt covenants into Q4 of this year and become operating cash flow breakeven during the second half of 2016; and, the Company's previously stated guidance of four additional OEM or private label partners to be announced during the balance of 2015. These statements are preliminary estimates and reflect the best judgment of our management, but involve a number of risks and uncertainties which could cause actual results to differ materially from those set forth in our estimates. Consequently, there can be no assurances that actual results for the year ending December 31, 2015 will be within the range of the preliminary estimates set forth above or that the Company will enter secure additional OEM or Private Label partners. Any variation between our actual results and the estimates set forth above may be material. We do not expect to disclose publicly whether or not our preliminary financial and operating results have changed, or to update such results, other than through the release of actual results in the ordinary course of business. Additional forward-looking statements include statement with respect to Amedica's market opportunities, growth, future products, market acceptance of its products, sales and financial results. Such statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica's other filings with the SEC.  Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

 
Amedica Corporation
Consolidated Balance Sheets – Unaudited
(in thousands, except share and per share data)
     
  March 31, 2015 December 31, 2014
Assets    
Current assets:    
Cash and cash equivalents  $ 14,882  $ 18,247
Trade accounts receivable, net of allowance of $60 and $54, respectively  2,568  2,513
Prepaid expenses and other current assets  1,464  1,247
Inventories, net  11,197  11,675
Total current assets  30,111  33,682
Property and equipment, net  3,286  3,515
Intangible assets, net  4,063  4,188
Goodwill  6,163  6,163
Other long-term assets  35  35
Total assets  $ 43,658  $ 47,583
Liabilities and stockholders' equity (deficit)    
Current liabilities:    
Accounts payable  $ 1,217  $ 778
Accrued liabilities  3,117  3,146
Current portion of long-term debt  19,157  19,070
Total current liabilities  23,491  22,994
Deferred rent  497  517
Long-term debt  3,110  3,061
Other long-term liabilities  134  134
Derivative liabilities  13,245  13,970
Commitments and contingencies    
Stockholders' equity (deficit):    
Common stock, $0.01 par value; 250,000,000 shares authorized; 29,092,095 and 26,353,666 shares issued at March 31, 2015 and December 31, 2014, respectively  291  264
Additional paid-in capital  180,896  179,148
Treasury Stock  (120)  —
Accumulated deficit  (177,886)  (172,505)
Total stockholders' equity  3,181  6,907
Total liabilities, convertible preferred stock and stockholders' equity (deficit)  $ 43,658  $ 47,583
 
 
Amedica Corporation
Consolidated Statements of Operations and Comprehensive Loss – Unaudited
(in thousands, except share and per share data)
     
  Three Months Ended March 31,
  2015 2014
Product revenue  $ 4,743  $ 5,780
Costs of revenue  1,522  1,649
Gross profit  3,221  4,131
Operating expenses:    
Research and development  1,843  591
General and administrative  2,027  3,075
Sales and marketing  3,357  4,521
Total operating expenses  7,227  8,187
Loss from operations  (4,006)  (4,056)
Other income (expense):    
Interest income  —  3
Interest expense  (1,100)  (530)
Loss on extinguishment of debt  (79)  —
Change in fair value of derivative liabilities  (177)  (114)
Loss on extinguishment of derivative liabilities  (16)  —
Other expense  (3)  (16)
Total other income (expense)  (1,375)  (657)
Net loss before income taxes  (5,381)  (4,713)
Provision for income taxes  —  —
Net Comprehensive Loss  $ (5,381)  $ (4,713)
Net loss per share attributable to common stockholders:    
Basic and diluted  $ (0.20)  $ (0.79)
Weighted average common shares outstanding:    
Basic and diluted  26,929,447  5,967,400

Reconciliation of Non-GAAP Financial Measures:

To supplement our consolidated statements of operations and comprehensive net loss which are presented in accordance with GAAP, we use certain non-GAAP measures of components of financial performance. Although not measures of financial performance under GAAP, "Adjusted EBITDA" and "Gross Margin Before deducting the Provision for Excess and Obsolete Inventory" are provided for the use of investors in understanding our operating results and are not prepared in accordance with, nor do they serve as alternatives to GAAP measures, and may be materially different from similar measures used by other companies. We define "Adjusted EBITDA" as our earnings before deductions for interest, taxes, depreciation, amortization, stock-based compensation, change in fair value of derivative liabilities, offering costs and loss on extinguishment of debt.  We define "Gross Margin before Deducting the Provision for Excess and Obsolete Inventory" as our gross margin before deducting the provision for excess and obsolete inventory. While not a substitute for information prepared in accordance with GAAP, management believes that this information is helpful for investors to more easily understand our operating financial performance. Management also believes these measures may better enable an investor to form views of our potential financial performance in the future. These measures have limitations as analytical tools, and investors should not consider these measures in isolation or as a substitute for analysis of our results prepared in accordance with GAAP.

Below is a reconciliation of Adjusted EBITDA to Net Loss for each of the periods presented (in thousands - unaudited):

  Three Months Ended March 31,
  2015 2014
Net Loss  (5,381)  (4,713)
Interest expense, net  1,100  530
Depreciation  428  433
Amortization  125  125
Stock-based compensation  592  1,404
Change in fair value of derivative liabilities  177  114
Loss on extinguishment of debt  79  —
Adjusted EBITDA  (2,880)  (2,107)

Below is a reconciliation of Gross Profit and Margin to Gross Profit and Margin Before deducting the Provision for Excess and Obsolete Inventory for each of the periods presented (in thousands - unaudited): 

  Three Months Ended March 31, 2015 Three Months Ended March 31, 2014
  Gross Profit Gross Margin Gross Profit Gross Margin
Gross profit and margin $ 3,221 67.9% $ 4,131 71.5%
Provision for excess and obsolete inventory 326 6.9% 415 7.2%
Gross profit and margin, excluding provision for excess and obsolete inventory $ 3,547 74.8% $ 4,546 78.7%

Mike Houston Director of Investor Relations 801-839-3534

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 13

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 148

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 221

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 199

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 53

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 83

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

US Agriculture Partners with CeresAI for Enhanced Farming Insights

Updated Category News Views 168

US Agriculture and CeresAI: A Groundbreaking Collaboration In an innovative move, US Agriculture, LLC has teamed up with CeresAI to transform farmland monitoring through advanced technology. This partnership aims to leverage artificial intelligence for improved performance in agricultural investments by optimizing farmland management and reducing costs associated with...

Continue Reading
Infosys Launches New Zurich Office to Drive AI Innovations

Updated Category News Views 175

Infosys Expands Its Zurich Office for Enhanced Client Collaboration Infosys, a global trailblazer in digital services and consulting, has inaugurated its new office in Zurich, Switzerland, marking a pivotal moment in its 25-year journey within the Swiss market. With this move, Infosys not only relocates its Swiss headquarters to The Circle at Zurich Airport but also...

Continue Reading
SierraConstellation Partners Celebrates Significant Award Wins

Updated Category News Views 117

A Major Milestone for SierraConstellation Partners SierraConstellation Partners (“SCP”), a foremost interim management and advisory firm, has received several prestigious awards for its outstanding work in business restructuring. The Global M&A Network has recognized SCP's exemplary handling of both the sale of Vyera Pharmaceuticals' assets and the reorganization of...

Continue Reading
Kaltura's AI Innovations Recognized in Market Guide

Updated Category News Views 179

Kaltura's Recognition in the Industry Kaltura, a leader in AI Video Experience Cloud technology, has recently been acknowledged as a Representative Vendor in the Gartner Market Guide for Video Platform Services. This recognition is a testament to Kaltura's forward-thinking approach and its commitment to enhancing enterprise video solutions. The Importance of Video...

Continue Reading
Liberty Gold’s Annual Meeting Outcomes: New Leadership and Directions

Updated Category News Views 288

Liberty Gold Announces Annual General Meeting Results Vancouver, British Columbia – Liberty Gold Corp. (TSX: LGD; OTCQX: LGDTF) has shared the outcomes of its recent Annual General Meeting (AGM) where shareholders participated in crucial decisions shaping the future leadership of the company. The AGM marked a significant moment for Liberty Gold as it transitions into a...

Continue Reading